Hyundai BioLand Co Ltd
KOSDAQ:052260
Hyundai BioLand Co Ltd
Research & Development
Hyundai BioLand Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hyundai BioLand Co Ltd
KOSDAQ:052260
|
Research & Development
-₩7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-7%
|
|
|
AmorePacific Corp
KRX:090430
|
Research & Development
-₩102.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Amorepacific Group
KRX:002790
|
Research & Development
-₩103.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Cosmax Inc
KRX:192820
|
Research & Development
-₩2.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
LG H&H Co Ltd
KRX:051900
|
Research & Development
-₩21.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-2%
|
|
|
Kolmar Korea Co Ltd
KRX:161890
|
Research & Development
-₩30.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-36%
|
|
Hyundai BioLand Co Ltd
Glance View
HYUNDAI BIOLAND Co., Ltd. engages in the manufacture and sale of pharmaceutical and functional products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2001-05-17. The firm operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.
See Also
What is Hyundai BioLand Co Ltd's Research & Development?
Research & Development
-7B
KRW
Based on the financial report for Sep 30, 2025, Hyundai BioLand Co Ltd's Research & Development amounts to -7B KRW.
What is Hyundai BioLand Co Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-7%
Over the last year, the Research & Development growth was 9%. The average annual Research & Development growth rates for Hyundai BioLand Co Ltd have been 3% over the past three years , 1% over the past five years , and -7% over the past ten years .
